0.78
+0.0206(+2.71%)
Currency In USD
| Previous Close | 0.76 |
| Open | 0.76 |
| Day High | 0.81 |
| Day Low | 0.75 |
| 52-Week High | 4.65 |
| 52-Week Low | 0.72 |
| Volume | 365,339 |
| Average Volume | 446,805 |
| Market Cap | 52.14M |
| PE | -0.36 |
| EPS | -2.19 |
| Moving Average 50 Days | 1.12 |
| Moving Average 200 Days | 2.3 |
| Change | 0.02 |
If you invested $1000 in Generation Bio Co. (GBIO) since IPO date, it would be worth $31.62 as of February 05, 2025 at a share price of $0.781. Whereas If you bought $1000 worth of Generation Bio Co. (GBIO) shares 3 years ago, it would be worth $135.29 as of February 05, 2025 at a share price of $0.781.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
GlobeNewswire Inc.
Jan 06, 2025 9:30 PM GMT
Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivoPrograms to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseasesCompany reorg
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 06, 2024 9:05 PM GMT
Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
GlobeNewswire Inc.
Sep 12, 2024 8:05 PM GMT
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief